Previous work showed that KRAS-induced ERK signaling conferred cell resistance to vorinostat, a histone deacetylase (HDAC) inhibitor and FDA-approved drug for treating cutaneous T-cell lymphoma (Wang et al, 2016). The gene discussed is KRAS; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.